JP2017503481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503481A5 JP2017503481A5 JP2016536527A JP2016536527A JP2017503481A5 JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5 JP 2016536527 A JP2016536527 A JP 2016536527A JP 2016536527 A JP2016536527 A JP 2016536527A JP 2017503481 A5 JP2017503481 A5 JP 2017503481A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- lenalidomide
- patient
- pharmaceutically acceptable
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| US61/913,046 | 2013-12-06 | ||
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503481A JP2017503481A (ja) | 2017-02-02 |
| JP2017503481A5 true JP2017503481A5 (enExample) | 2018-01-18 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536527A Pending JP2017503481A (ja) | 2013-12-06 | 2014-12-05 | 血液癌を治療する方法及び免疫調節療法に対する臨床的感受性の予測因子としてのバイオマーカーの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (enExample) |
| EP (1) | EP3077547A4 (enExample) |
| JP (1) | JP2017503481A (enExample) |
| KR (1) | KR20160090390A (enExample) |
| AU (1) | AU2014360316A1 (enExample) |
| BR (1) | BR112016012792A2 (enExample) |
| CA (1) | CA2932266A1 (enExample) |
| EA (1) | EA201691143A1 (enExample) |
| IL (1) | IL245936A0 (enExample) |
| MX (1) | MX2016007179A (enExample) |
| PH (1) | PH12016501023A1 (enExample) |
| WO (1) | WO2015085160A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| EP3207521B1 (en) * | 2014-10-17 | 2022-11-02 | Stichting Maastricht Radiation Oncology "Maastro Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| WO2017044793A1 (en) | 2015-09-11 | 2017-03-16 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of cereblon |
| AU2016326499A1 (en) * | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| WO2019065901A1 (ja) * | 2017-09-29 | 2019-04-04 | 国立大学法人九州大学 | びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| AU2020372333B2 (en) * | 2019-10-21 | 2026-08-06 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158740A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2710196A1 (en) * | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| TWI509247B (zh) * | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2014
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
-
2016
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500110A5 (enExample) | ||
| RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
| Wu et al. | Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone | |
| JP2014144959A5 (enExample) | ||
| BR112017025254A2 (pt) | ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento? | |
| JP2016537010A5 (enExample) | ||
| Jang et al. | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma | |
| JP2016536303A5 (enExample) | ||
| Zhang et al. | The renewed battle against RAS-mutant cancers | |
| JP2016501013A5 (enExample) | ||
| WO2018007872A9 (en) | Biomarkers for inflammatory bowel disease | |
| WO2015057968A3 (en) | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same | |
| Chen et al. | Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel | |
| JP2016510591A5 (enExample) | ||
| JP2016540726A5 (enExample) | ||
| Wang et al. | Effects of miR-455 on PIK3R1 gene expression regulation and kidney cancer cell functions. | |
| WO2023023592A1 (en) | Repurposing drugs for non-small cell lung cancer | |
| MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
| Bialopiotrowicz et al. | Microenvironment-induced expression of PIM kinases supports chronic lymphocytic leukemia cells survival and promotes CXCR4-mTOR pathway dependent migration | |
| An et al. | Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy | |
| Lee et al. | Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma | |
| Li et al. | Expression of high mobility group box-1 in colorectal cancer and its clinical significance | |
| Deig et al. | Blood-based nucleic acid biomarkers as a potential tool to determine radiation therapy response in non-small cell lung cancer | |
| Ha et al. | Superiority of Epstein-Barr virus (EBV) DNA in the plasma over whole blood in prognostication of extranodal NK/T cell lymphoma, nasal type (ENKTL) | |
| Qi et al. | Detection and clinical significance of platelet derived growth factor-BB and microvessel density in clear cell renal cell carcinoma |